Observational analysis reports increased epithelial-mesenchymal transition markers in metastatic colorectal cancer, suggesting novel therapeutic targets.
Introduction: Globally, colorectal cancer (CRC) continues to be a major cause of cancer-related morbidity and death, with metastasis—particularly to the liver—significantly worsening patient outcomes. Objective: The aim of this study was to investigate the expression of key epithelial-mesenchymal transition (EMT) transcription factors (Snail family transcriptional repressor 1 [SNAI1], zinc finger e-box binding homeobox 1 [ZEB1], Slug, Twist, and metastasis-associated protein 3 [MTA3]) and the pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-α) in CRC cases with and without metastasis to the liver. Methods: A total of 41 CRC patients (20 non-metastatic, 21 with liver metastasis) from Dr. Sardjito General Hospital, Yogyakarta, were examined utilizing reverse transcription quantitative polymerase chain reaction of the adjacent normal tissues and the tumors. Results: SNAI1, ZEB1, Slug, Twist, and TNF-α were significantly upregulated in metastatic CRC, while MTA3 was downregulated. Expression of these markers correlated with body mass index, liver enzymes (aspartate aminotransferase), and cancer stage. Conclusion: These findings highlight the central role of EMT-related transcription factors and inflammatory signaling in CRC metastasis and suggest that targeting these pathways could offer novel therapeutic strategies for metastatic CRC.
No takes yet. Share an insight, caveat, or question.
Handaya et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: